US Says CBP Seized Entry in Customs Suit for Containing Controlled Substance
The U.S. told the Court of International Trade on Sept. 18 that CBP seized an entry of 7-keto dehydroepiandrosterone at issue in a suit brought by importer UniChem Enterprises (UniChem Enterprises v. United States, CIT # 24-00033).
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
Previously, the Drug Enforcement Administration told CBP it believed the entry to be a Schedule III anabolic steroid whose importation violates DEA regulations (see 2406250071). The DEA recommended that CBP seize the entry on the DEA's behalf.
The entry was intercepted by the DEA on the suspicion that it contained a controlled substance. UniChem said the product is a commonly used dietary supplement and that CBP detained the entry for too long without legal authority. CBP moved to dismiss the case for lack of jurisdiction, since no protestable decision was made on the entry given that the entry was detained pending a DEA decision (see 2404090029).
The status report said the entry has now been seized by CBP.